Clinical Trials Logo

Donor Lymphocyte Infusion clinical trials

View clinical trials related to Donor Lymphocyte Infusion.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02673008 Completed - Clinical trials for Hematopoietic Stem Cell Transplantation

MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT

Start date: January 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Allogeneic hematopoietic cell transplantation (Allo-HSCT) is an effective therapy for acute leukemia, but relapse remains an important problem. Therapy options for relapse include stopping immune suppression, re-induction of chemotherapy, donor lymphocyte infusion (DLI), and another transplantation used alone or in combination. However, the efficacy of these interventions is limited. One approach to the relapse problem is to intervene before hematologic or pathologic relapse occurs based on minimal residual disease (MRD). In this study, the efficacy of MRD-directed DLI on transplantation outcomes will be evaluated in patients with acute leukemia receiving allo-HSCT.